Pfizer celebrates a year of achievements in 2015 annual review

PfizerPfizer Inc. (NYSE: PFE) has released its 2015 integrated annual review, an in-depth look into the company's financial, social and environmental performance. 2015 was marked by breakthrough scientific research, collaborations and partnerships. In the review, the scientists, researchers and business leaders offer in-depth looks at their projects and how they are working to discover and develop potential new medicines and vaccines to improve patient health.

"Our purpose at Pfizer is to bring therapies to patients that significantly improve their lives," said Pfizer Chairman and Chief Executive Officer Ian C. Read. "Thanks to the more than 97,000 Pfizer colleagues around the world, we met our yearly commitments and continued to build the company's capabilities toward our goal to become the world's premier, innovative biopharmaceutical company by the end of this decade."

As a result of our research as well as innovative collaborations with our peers and research partners, we saw great scientific progress across multiple therapeutic areas in 2015.

  • We advanced 39 potential new therapies in our R&D pipeline, representing the strongest progress in Pfizer's history.
  • Our research efforts in oncology have resulted in a broad and deep portfolio of compounds, including five immuno-oncology assets in human studies that have the potential to address the urgent therapeutic needs of cancer patients.
  • We advanced our investigational vaccines pipeline to research some of the most deadly infectious diseases that affect people of all ages.

In 2015, Pfizer made great strides to help ensure patients around the world have access to the Pfizer medicines and vaccines that are approved and available. "Our very license to operate depends on ensuring the medicines we make to improve patient health and wellbeing are available to as many people as possible," commented Sally Susman, Executive Vice President, Corporate Affairs. "Patient assistance is not a program or catchphrase, it is a commitment."

  • In 2015, we significantly expanded the eligibility of our U.S. patient assistance program, Pfizer RxPathways®. The program helped more than 250,000 people access our medicines during the year.
  • We continued global health partnerships including the International Trachoma Initiative at The Task Force for Global Health, which seeks to eliminate the world's leading cause of preventable blindness and marked 2015 with the 500 millionth dose donation of antibiotic Zithromax® (azithromycin).
  • 2015 was the 5th year of our partnership with Gavi, the Vaccine Alliance, in which we have pledged 740M doses of pneumococcal vaccines to immunize children in GAVI countries through 2025.
  • To address family planning needs of women in the developing world, our collaboration with the Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation (CIFF) completed its first-full year, and was successful in helping broaden access to injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), to tens of thousands of women across several countries in Africa and Asia.

Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer healthcare products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Most Popular Now

Novo Nordisk announces plans to transform its appr…

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious c...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

World's largest Alzheimer's survey reveals most ad…

Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest glob...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Discovery could explain failed clinical trials for…

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trial...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

Aspirin found not to prolong healthy aging

Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial p...

The Lancet Respiratory Medicine publishes first Ph…

AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

Clinical gene discovery program solves 30 medical …

A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has...